Stocks TelegraphStocks Telegraph
Stock Ideas

LAB Company Profile and Key Details

NASDAQ : LAB

Standard BioTools

$0.73
-0.0059-0.80%
Open: 4:00 PM
72.26
B-ESG ScoreESG Rating

Price Chart

Stock Price Today

Standard BioTools Inc. (LAB) stock declined over -0.80%, trading at $0.73 on NASDAQ, down from the previous close of $0.74. The stock opened at $0.76, fluctuating between $0.71 and $0.77 in the recent session.

Stock Snapshot

0.7401
Prev. Close
286.61M
Market Cap
0.705
Day Low
-18.35
P/E Ratio
-0.04
EPS (TTM)
-0.58
Cash Flow per Share
0.76
Open
390.37M
Number of Shares
0.7697
Day High
95.69%
Free Float in %
2.05
Book Value
35.13M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jun 26, 20260.740.770.700.7335.13M
Jun 25, 20260.770.800.730.743.01M
Jun 24, 20260.790.860.750.754.62M
Jun 23, 20260.780.830.780.794.71M
Jun 22, 20260.830.840.760.771.82M
Jun 18, 20260.830.840.800.833.29M
Jun 17, 20260.840.880.810.812.04M
Jun 16, 20260.840.870.830.832.34M
Jun 15, 20260.900.900.840.851.89M
Jun 12, 20260.890.930.880.891.75M
Jun 11, 20260.900.940.860.912.33M
Jun 10, 20260.890.920.870.885.58M
Jun 09, 20260.810.910.790.898.34M
Jun 08, 20261.141.140.800.8018.23M
Jun 05, 20261.271.281.111.153.5M
Jun 04, 20261.151.291.141.273.86M
Jun 03, 20261.141.181.101.143.58M
Jun 01, 20261.131.171.111.152.38M
May 29, 20261.121.191.101.157.02M
May 28, 20261.051.151.051.142.17M

Contact Details

Boston, MA 02109

United States

https://www.standardbio.com650 266 6000

About Company

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Company Information

Employees388
Beta1.38
Sales or Revenue$106.34M
5Y Sales Change%-0.528%
Fiscal Year EndsDecember
SectorHealthcare
IndustryMedical - Equipment & Services

Company Overview

Standard BioTools Inc. (NASDAQ:LAB) closed at $0.73 USD, losing -$0.01 (-0.80%) from the previous close of $0.74. The stock is currently within 5% of its 52-week low $0.70 and $1.72. With a market capitalization of about $286.61 million, Standard BioTools Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.38). Key stats such as the average daily volume over the past year has been around 3.60 million shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Standard BioTools Inc. operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Michael Egholm, the company employs approximately 388 people and listed since February 10, 2011. Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -4.14%, SMA50 -15.13%, SMA200 -9.3%). The stock’s 14-day RSI is 39.07 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.98% below its high and over 27.17% above its low. Average 10-day trading volume of 7.80 million shares is significantly above the 3-month average of 3.59 million, indicating heightened recent market interest.

Valuation Metrics

Standard BioTools Inc. trades at a P/E ratio of -2.87, slightly below the S&P 500 average, with a price-to-sales ratio of 3.25 and a price-to-book ratio of 0.5 suggesting the stock is closer to book value. The P/FCF stands at -2.97, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Standard BioTools Inc. generated EPS of -$0.20 over the past year. Five-year average earnings growth is 23.22%. Wall Street analysts project EPS growth of 15.3% annually over the next five years. The latest quarter delivered EPS of -$0.02. The next quarter is forecast at -$0.04. Next year's EPS is expected at $41.49. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.35 to $1.35. The high target offers 84.93% upside. The low target suggests 84.93% downside. The mean target is $1.35. This offers 84.93% upside. Standard BioTools Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 0.0%. The prior quarter beat by -300.0%. Over the last six quarters, Apple has recorded several small beats. These include -28.57% in February 26, 2025.

Shareholding & Insider Activity

Standard BioTools Inc. has 382.00 million shares outstanding. The public float is 48.39 million shares, elevated short interest at 5.39% of float. This equals 12.01 million shares. The short ratio is 7.42 days. Institutional investors hold 74.95% of the float. Insiders own 2.68%. Casdin Partners Master Fund, L.P. holds 72.10 million shares, Caligan Partners LP has 11.44 million shares and JOHNSON DAVID EDWARD has 11.19 million shares.

Price Forecast & Outlook

Our AI price prediction model suggests that Standard BioTools Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -26.45%, with price expected at $0.54 by July 10, 2026, within a range of $0.45 to $0.62 3-Month Outlook: Projected fall of -0.57%, reaching $0.73 by September 24, 2026, with a range of $0.67 to $0.78. 1-Year Outlook: Projected gain of 239.14%, with price at $2.49 by June 25, 2027, within a range of $0.00 to $2.67.

Key Takeaways

Standard BioTools Inc. (NASDAQ:LAB) shares are up 17.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Standard BioTools Inc. trading at a premium to the broader market with a P/E of -2.87. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $2.97, suggesting 304.52% upside. Our AI forecast model points to short-term weakness (-26.45% over two weeks), a medium-term fall (-0.57% over three months), and a longer-term gain (239.14% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Standard BioTools Inc. (LAB) stock price?
Standard BioTools Inc. (NASDAQ: LAB) stock price is $0.73 in the last trading session. During the trading session, LAB stock reached the peak price of $0.77 while $0.71 was the lowest point it dropped to. The percentage change in LAB stock occurred in the recent session was -0.8% while the dollar amount for the price change in LAB stock was - $0.01.
LAB's industry and sector of operation?
The NASDAQ listed LAB is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector. Standard BioTools Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of LAB?
Mr. Jeremy Steven Davis
Chief Commercial Officer
Dr. Stephen R. Quake D.phil., Ph.D.
Co-Founder & Chairman of Advisory Board
Mr. Andrew Quong Ph.D.
Chief Science Officer
Mark Spearman
Senior Director of Corporation Communications
Mr. Jeffrey G. Black
Senior Vice President & Chief Financial Officer
Dr. David A. King Ph.D.
Senior Vice President of Global R&D
Dr. Michael Egholm Ph.D.
Pres, Chief Executive Officer & Director
Mr. Hanjoon Kim
Chief Operating Officer
Ms. Agnieszka M. Gallagher J.D.
Senior Vice President & Chief Legal Officer
Steve Kulisch
Senior Vice President, GM & Head of Strategic Marketing
Mr. Vikram Jog
Chief Financial Officer
Mr. Stephen Christopher Linthwaite
Advisor
Ms. Angela Peters
Chief HR Officer
Mr. Rafael Aguirre-Sacasa
Acting Gen. Counsel
Ms. Mona Abou-Sayed
Senior Vice President of SBS
Mr. Peter DeNardo
Senior Director of Investor Relations & Corporation Communications
How LAB did perform over past 52-week?
LAB's closing price is 4.14% higher than its 52-week low of $0.70 where as its distance from 52-week high of $1.72 is -57.31%.
How many employees does LAB have?
Number of LAB employees currently stands at 388.
Link for LAB official website?
Official Website of LAB is: https://www.standardbio.com
How do I contact LAB?
LAB could be contacted at phone 650 266 6000 and can also be accessed through its website. LAB operates from 50 Milk Street, Boston, MA 02109, United States.
How many shares of LAB are traded daily?
LAB stock volume for the day was 35.13M shares. The average number of LAB shares traded daily for last 3 months was 3.6M.
What is the market cap of LAB currently?
The market value of LAB currently stands at $286.61M with its latest stock price at $0.73 and 390.37M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph